Global Next Generation Antibody Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Next Generation Antibody Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.

According to our (Global Info Research) latest study, the global Next Generation Antibody Therapeutics market size was valued at US$ 12610 million in 2023 and is forecast to a readjusted size of USD 47260 million by 2030 with a CAGR of 21.0% during review period.

Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 percent.

This report is a detailed and comprehensive analysis for global Next Generation Antibody Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Next Generation Antibody Therapeutics market size and forecasts, in consumption value ($ Million), 2019-2030

Global Next Generation Antibody Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2019-2030

Global Next Generation Antibody Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030

Global Next Generation Antibody Therapeutics market shares of main players, in revenue ($ Million), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Next Generation Antibody Therapeutics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Next Generation Antibody Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Takeda, Daiichi Sankyo, Seagen, Astellas, Immunomedics, GSK, Immunocore, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Next Generation Antibody Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Next Generation Antibody Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)

Market segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases

Market segment by players, this report covers
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Next Generation Antibody Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Next Generation Antibody Therapeutics, with revenue, gross margin, and global market share of Next Generation Antibody Therapeutics from 2019 to 2024.

Chapter 3, the Next Generation Antibody Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Next Generation Antibody Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Next Generation Antibody Therapeutics.

Chapter 13, to describe Next Generation Antibody Therapeutics research findings and conclusion.